Myelodysplastic syndrome in young adults: case series.
DOI:
https://doi.org/10.32818/reccmi.a3n1a4Keywords:
young adult, myelodysplastic syndrome, allogeneic bone marrow transplantation.Abstract
Myelodysplastic syndromes comprises to a heterogeneous group of hematopoietic stem cell malignancies characterized by ineffective and dysplastic bone marrow production related to qualitative and quantitative functional defects of the three cell lines resulting in systemic manifestations such as anemia, risk of bleeding and infection, with a variable risk of transformation to acute myeloid leukemia. It occurs more frequently in older adults with a median age at diagnosis of 65 years. We report a series of 3 cases of young adult patients characterized mainly by high transfusion requirement and in whom the diagnosis of myelodysplastic syndrome was made. Initial treatment with azacitidine is offered resulting in an early progression to acute myeloid leukemia in two of them. The third case is currently under management with this scheme. In the first two cases mentioned above, salvage management was performed with 7+3 chemotherapy protocol resulting in remission in the first with subsequent consolidation with allogeneic bone marrow transplantation having a good evolution thereafter. The second case results in relapse being undergone to rescue protocol with IDA-FLAG protocol without achieving remission, dying of infectious complications.
Downloads
Metrics
References
García-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol. 2015; 90(9): 831-841.
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by subtype: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011; 105(11): 1684-1692.
Mora GE, Espinosa D, Casas C, Abello V, Solano MH. Caracterización clínica de los pacientes con síndrome mielodisplásico. Acta Medica Colombiana. 2016; 41: 36-41.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937-951.
Kantarjian H, O’Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6): 1351-1361.
Marisavljevic D, Savic A, Zeremski V, Stanisavljevic N, Jelic S. Myelodysplastic syndromes in adults aged less than 50 years: incidence and clinicopathological data. Journal of BUON: official journal of the Balkan Union of Oncolo- gy. 2014; 19(4): 999-1005.
Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, et al. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution’s Experience. Clinical lymphoma, myeloma & leukemia. 2016; 16 Suppl: S53-56.
Cseh AM, Niemeyer CM, Yoshimi A, Catala A, Fruhwald MC, Hasle H, et al. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group. British journal of haematology. 2016; 172(6): 930- 936.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Camilo Andrés García-Prada, Humberto Martínez-Cordero, Orlando Bonell Patiño-Escobar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
